Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
Taiwan · Delayed Price · Currency is TWD 29.80
-0.05 (-0.17%)
Jan 22, 2026, 1:30 PM CST
TPEX:4111 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 165.35 | 110.63 | 68.67 | 154.01 | 80.75 | 59.14 | Upgrade |
Depreciation & Amortization | 72.52 | 66.3 | 61.96 | 72.88 | 79.08 | 84.14 | Upgrade |
Loss (Gain) From Sale of Assets | 1.17 | 2.38 | 0.13 | 4.96 | -0.12 | -0.2 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | - | -6.8 | - | Upgrade |
Provision & Write-off of Bad Debts | 0.01 | 0.01 | - | -0 | 0 | 0.01 | Upgrade |
Other Operating Activities | 56.93 | 26.08 | -17.01 | -17.16 | 32.71 | -4.96 | Upgrade |
Change in Accounts Receivable | -51.46 | -28.25 | -26.6 | 9.17 | -36.81 | 38.27 | Upgrade |
Change in Inventory | -2.24 | -7.68 | 9.86 | -8.83 | -4.86 | 0.13 | Upgrade |
Change in Accounts Payable | 132.48 | 22.41 | -16.49 | 17.5 | 4.76 | -5.82 | Upgrade |
Change in Unearned Revenue | -0.29 | -1.03 | -3.6 | -3.02 | -4.21 | 7.2 | Upgrade |
Change in Other Net Operating Assets | -129.63 | 22.34 | -2.4 | 10.63 | 21.78 | -34.37 | Upgrade |
Operating Cash Flow | 244.85 | 213.2 | 74.52 | 214.86 | 139.33 | 143.53 | Upgrade |
Operating Cash Flow Growth | 40.31% | 186.10% | -65.32% | 54.21% | -2.93% | -11.92% | Upgrade |
Capital Expenditures | -96.59 | -84.19 | -101.5 | -105.33 | -264.86 | -22.01 | Upgrade |
Sale of Property, Plant & Equipment | 0.21 | 0.31 | 0.41 | 0.07 | 0.12 | 0.39 | Upgrade |
Divestitures | - | - | - | 168.97 | - | - | Upgrade |
Sale (Purchase) of Intangibles | -0.84 | -1.03 | -0.5 | -0.52 | -0.65 | -0.78 | Upgrade |
Sale (Purchase) of Real Estate | -1.86 | - | - | - | - | -0.35 | Upgrade |
Investment in Securities | - | - | - | - | 1.37 | - | Upgrade |
Other Investing Activities | -2.62 | -1.4 | 24.97 | 0.06 | -25 | 2.18 | Upgrade |
Investing Cash Flow | -101.7 | -86.31 | -76.61 | 63.24 | -289.02 | -20.56 | Upgrade |
Short-Term Debt Issued | - | - | - | - | 130 | - | Upgrade |
Total Debt Issued | - | - | - | - | 130 | - | Upgrade |
Short-Term Debt Repaid | - | -110 | - | -10 | - | - | Upgrade |
Long-Term Debt Repaid | - | -4.77 | -5.65 | -7.03 | -6.46 | -6.44 | Upgrade |
Total Debt Repaid | -41.35 | -114.77 | -5.65 | -17.03 | -6.46 | -6.44 | Upgrade |
Net Debt Issued (Repaid) | -41.35 | -114.77 | -5.65 | -17.03 | 123.54 | -6.44 | Upgrade |
Common Dividends Paid | - | -56.98 | -68.38 | -56.98 | -56.98 | -56.98 | Upgrade |
Other Financing Activities | 0.02 | 0 | 0.92 | -0.87 | 0.12 | -0.01 | Upgrade |
Financing Cash Flow | -41.34 | -171.75 | -73.11 | -74.88 | 66.68 | -63.43 | Upgrade |
Foreign Exchange Rate Adjustments | - | - | - | 0.77 | -0.52 | 1.07 | Upgrade |
Net Cash Flow | 101.81 | -44.86 | -75.21 | 203.98 | -83.53 | 60.61 | Upgrade |
Free Cash Flow | 148.26 | 129.01 | -26.98 | 109.53 | -125.53 | 121.53 | Upgrade |
Free Cash Flow Growth | 75.55% | - | - | - | - | -3.89% | Upgrade |
Free Cash Flow Margin | 10.89% | 11.07% | -2.54% | 9.58% | -12.28% | 12.41% | Upgrade |
Free Cash Flow Per Share | 2.46 | 2.15 | -0.45 | 1.82 | -2.09 | 2.02 | Upgrade |
Cash Interest Paid | 0.65 | 1.85 | 1.44 | 1.5 | 1.03 | 0.16 | Upgrade |
Cash Income Tax Paid | - | 1.41 | 34.74 | 25.39 | 18.44 | 29.42 | Upgrade |
Levered Free Cash Flow | 150.81 | 40.28 | -50.71 | 105.66 | -140.99 | 111.05 | Upgrade |
Unlevered Free Cash Flow | 151.2 | 41.37 | -49.8 | 106.61 | -140.31 | 111.15 | Upgrade |
Change in Working Capital | -51.14 | 7.79 | -39.24 | 25.45 | -19.35 | 5.41 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.